Celldex Therapeutics Announces Upcoming Presentation at Lazard Capital Markets Healthcare Conference

Celldex Therapeutics Announces Upcoming Presentation at Lazard Capital Markets Healthcare Conference

Celldex Therapeutics, Inc.Sarah Cavanaugh, 781-433-3161Vice President of IR & Corp CommorBMC CommunicationsBrad Miles, 646-513-3125

(NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Lazard Capital Markets 9th Annual Healthcare Conference on Tuesday, November 13, 2012 at 9:30 am ET at The Pierre Hotel in New York City.

A of the presentation will be available online on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit .

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.